24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
TEMALIEVA 250MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | TEMALIEVA 250MG |
|---|---|
| Composition | Temozolomide Capsules IP 250mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (5 cap) |
| Country of Origin | India |
TEMALIEVA 250MG (Temozolomide Capsules IP 250mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
TEMALIEVA 250 MG (Temozolomide Capsules IP 250 mg) is a prescription anticancer medicine containing Temozolomide 250 mg, an oral chemotherapy agent used primarily for the treatment of certain types of brain tumors. It belongs to a class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells, preventing them from growing and multiplying.
Brain tumors can be aggressive and difficult to treat due to their location and complex nature. Temozolomide has become an important component of modern neuro-oncology treatment because of its ability to cross the blood-brain barrier and directly target tumor cells within the brain. This unique characteristic makes it particularly effective in the management of specific malignant brain tumors.
TEMALIEVA 250 MG is commonly prescribed for patients diagnosed with Glioblastoma Multiforme (GBM), one of the most aggressive forms of brain cancer, and Anaplastic Astrocytoma, a malignant brain tumor arising from astrocyte cells. It may be used alone or in combination with radiation therapy and other treatment modalities as part of a comprehensive cancer management plan.
Unlike many traditional chemotherapy medicines that require intravenous administration, Temozolomide is available in capsule form, offering greater convenience and flexibility for patients undergoing long-term treatment.
The medicine is often prescribed during both initial treatment and maintenance therapy phases, depending on the patient’s diagnosis, treatment response, and oncologist's recommendations.
TEMALIEVA 250 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Temozolomide therapy require regular blood tests, complete blood count monitoring, liver function assessments, and clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy in brain cancer treatment, TEMALIEVA 250 MG has become a trusted option in modern oncology and neuro-oncology care worldwide.
TEMALIEVA 250 MG (Temozolomide Capsules IP 250 mg) is primarily used in the treatment and management of malignant brain tumors.
The medicine is widely prescribed for newly diagnosed and recurrent glioblastoma patients.
Temozolomide is commonly used in patients with anaplastic astrocytoma following surgery or radiation therapy.
The medicine plays an important role in comprehensive brain cancer treatment programs.
Doctors may prescribe Temozolomide when brain tumors return after previous treatment.
The medicine may be used as maintenance treatment to help control tumor growth.
Temozolomide is often administered alongside radiation therapy and other oncology treatments.
The medicine is a key component of modern neuro-oncology care.
Temozolomide belongs to a class of medicines known as Alkylating Agents.
TEMALIEVA works by:
This mechanism helps reduce the ability of cancer cells to grow and spread within the body.
Like all medicines, TEMALIEVA 250 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Nausea is one of the most commonly reported side effects during treatment.
Some patients may experience vomiting after taking the medicine.
Weakness and tiredness may occur throughout therapy.
Reduced appetite may affect nutritional intake.
Digestive disturbances such as constipation may develop.
Some individuals may experience headaches during treatment.
Temporary hair thinning or hair loss may occur.
Temozolomide may lower white blood cells, red blood cells, and platelets.
Occasional dizziness may be experienced by some patients.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of TEMALIEVA 250 MG (Temozolomide Capsules IP 250 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the specific brain tumor being treated.
Temozolomide dosing is commonly based on body surface area calculations.
Regular blood count monitoring helps guide dosage adjustments.
Doctors may modify treatment according to effectiveness and tolerance.
Radiation therapy and other medicines may influence treatment planning.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, vitamins, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for the treatment of glioblastoma multiforme, anaplastic astrocytoma, and certain malignant brain tumors.
Temozolomide is an oral chemotherapy medicine that damages cancer cell DNA and helps slow tumor growth.
Yes. Temozolomide is a chemotherapy medicine classified as an alkylating agent.
Yes. One of its key advantages is its ability to reach brain tissue and target tumor cells effectively.
Yes. It is commonly prescribed alongside radiation therapy for newly diagnosed glioblastoma.
Yes. It may lower white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
Yes. Blood tests, liver function assessments, and routine clinical evaluations are essential throughout therapy.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and neuro-oncology treatment.